» Articles » PMID: 30763568

Implications of Microglia in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia

Overview
Journal J Mol Biol
Publisher Elsevier
Date 2019 Feb 15
PMID 30763568
Citations 38
Authors
Affiliations
Soon will be listed here.
Abstract

Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are neurodegenerative disorders with clear similarities regarding their clinical, genetic and pathological features. Both are progressive, lethal disorders, with no current curative treatment available. Several genes that correlated with ALS and FTD are implicated in the same molecular pathways. Strikingly, many of these genes are not exclusively expressed in neurons, but also in glial cells, suggesting a multicellular pathogenesis. Moreover, chronic inflammation is a common feature observed in ALS and FTD, indicating an essential role of microglia, the resident immune cells of the central nervous system, in disease development and progression. In this review, we will provide a comprehensive overview of the implications of microglia in ALS and FTD. Specifically, we will focus on the role of impaired phagocytosis and increased inflammatory responses and their impact on microglial function. Several genes associated with the disorders can directly be linked to microglial activation, phagocytosis and neuroinflammation. Other genes associated with the disorders are implicated in biological pathways involved in protein degradation and autophagy. In general such mutations have been shown to cause abnormal protein accumulation and impaired autophagy. These impairments have previously been linked to affect the innate immune system in the central nervous system through inappropriate activation of microglia and neuroinflammation, highlighted in this review. Although it has been well established that microglia play essential roles in neurodegenerative disorders, the precise underlying mechanisms remain to be elucidated.

Citing Articles

Loss of MEF2C function by enhancer mutation leads to neuronal mitochondria dysfunction and motor deficits in mice.

Yousefian-Jazi A, Kim S, Chu J, Choi S, Nguyen P, Park U Mol Neurodegener. 2025; 20(1):16.

PMID: 39920775 PMC: 11806887. DOI: 10.1186/s13024-024-00792-y.


Microglial senescence in neurodegeneration: Insights, implications, and therapeutic opportunities.

Samuel Olajide T, Oyerinde T, Omotosho O, Okeowo O, Olajide O, Ijomone O Neuroprotection. 2024; 2(3):182-195.

PMID: 39364217 PMC: 11449118. DOI: 10.1002/nep3.56.


Interpretation of Neurodegenerative GWAS Risk Alleles in Microglia and their Interplay with Other Cell Types.

Holtman I, Glass C, Nott A Adv Neurobiol. 2024; 37:531-544.

PMID: 39207711 DOI: 10.1007/978-3-031-55529-9_29.


Impairment of Nrf2 signaling in the hippocampus of P301S tauopathy mice model aligns with the cognitive impairment and the associated neuroinflammation.

Mohamed A, ElKaffas M, Metwally K, Abdelfattah M, Elsery E, Elshazly A J Inflamm (Lond). 2024; 21(1):29.

PMID: 39107774 PMC: 11304845. DOI: 10.1186/s12950-024-00396-9.


Copper toxicity and deficiency: the vicious cycle at the core of protein aggregation in ALS.

Min J, Sarlus H, Harris R Front Mol Neurosci. 2024; 17:1408159.

PMID: 39050823 PMC: 11267976. DOI: 10.3389/fnmol.2024.1408159.